Back to Search
Start Over
Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune‐related lncRNA
- Source :
- Cancer Medicine, Vol 10, Iss 18, Pp 6561-6575 (2021), Cancer Medicine
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Background The composition of the population of immune‐related long non‐coding ribonucleic acid (irlncRNA) generates a signature, irrespective of expression level, with potential value in predicting the survival status of patients with invasive breast carcinoma. Methods The current study uses univariate analysis to identify differentially expressed irlncRNA (DEirlncRNA) pairs from RNA‐Seq data from The Cancer Genome Atlas (TCGA). 36 pairs of DEirlncRNA pairs were identified. Using various algorithms to construct a model, we have compared the area under the curve and calculated the 5‐year curve of Akaike information criterion (AIC) values, which allows determination of the threshold indicating the maximum value for differentiation. Through cut‐off point to establish the optimal model for distinguishing high‐risk or low‐risk groups among breast cancer patients. We assigned individual patients with invasive breast cancer to either high risk or low risk groups depending on the cut‐off point, re‐evaluated the tumor immune cell infiltration, the effectiveness of chemotherapy, immunosuppressive biomarkers, and immunotherapy. Results After re‐assessing patients according to the threshold, we demonstrated an effective means of distinguish the severity of the disease, and identified patients with different clinicopathological characteristics, specific tumor immune infiltration states, high sensitivity to chemotherapy,wellpredicted response to immunotherapy and thus a more favorable survival outcome. Conclusions The current study presents novel findings regarding the use of irlncRNA without the need to predict precise expression levels in the prognosis of breast cancer patients and to indicate their suitability for anti‐tumor immunotherapy.<br />The manuscript is an immune‐related lncRNA pairing strategy to construct a risk assessment model. We did not use precise expression levels of the target lncRNAs in the signature.
- Subjects :
- Oncology
Cancer Research
medicine.medical_treatment
Disease
Kaplan-Meier Estimate
Tumor Microenvironment
Breast
RNA-Seq
Immune Checkpoint Inhibitors
tumor‐infiltrating immune
Research Articles
Mastectomy
RC254-282
education.field_of_study
Univariate analysis
Framingham Risk Score
Carcinoma, Ductal, Breast
Area under the curve
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Middle Aged
Prognosis
Neoadjuvant Therapy
Gene Expression Regulation, Neoplastic
Survival Rate
Chemotherapy, Adjuvant
Female
RNA, Long Noncoding
immunotherapy
Research Article
medicine.medical_specialty
Bioinformatics
Population
Breast Neoplasms
risk score
Risk Assessment
Immune system
Breast cancer
breast cancer
Internal medicine
medicine
Biomarkers, Tumor
Humans
Radiology, Nuclear Medicine and imaging
education
business.industry
Gene Expression Profiling
Immunotherapy
TCGA
medicine.disease
LncRNA
Drug Resistance, Neoplasm
business
Subjects
Details
- Language :
- English
- ISSN :
- 20457634
- Volume :
- 10
- Issue :
- 18
- Database :
- OpenAIRE
- Journal :
- Cancer Medicine
- Accession number :
- edsair.doi.dedup.....cee3b4fe0a321e8a41bed41e91d489ef